Myfortic® versus Neoral® as long-term treatment in patients with severe atopic dermatitis: a randomized-controlled trial.

Completed

• Registration Number: NL-OMON24713

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

1. Age from 18 years;

2. Atopic dermatitis according to the criteria of Hanifin and Rajka;

Exclusion Criteria

1. Oral immunosuppressive treatment in the last 6 weeks;

2. Concomitant UV therapy;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical severity score: LSS.

Secondary Outcome Measures

Name	Time	Method
1. Physician global assessment score (PGA);<br /><br>2. Serum levels of thymus and activation and regulated chemokine (TARC);<br /><br>3. Itch (Visual analogue score, VAS);<br /><br>4. Amount of topical steroids that is used;<br /><br>5. Quality of life, measured with the Dermatology Life Quality Index (DLQI) of Finlay.